SEC Form 4Coverage since May 21, 2026
$BBIO insider trading
Over the last 12 months, BridgeBio Pharma insiders reported no purchases and 8 sales totaling $29.4M across SEC Form 4 filings. 100% of the activity was filed under pre-arranged 10b5-1 trading plans.
- Bought · 12m
- — 0 events
- Sold · 12m
- $29.4M 8 events
- Events · 12m
- 8 Form 4 filings, grouped
- Insiders · 12m
- 5 distinct reporters
- 10b5-1 share
- 100% pre-arranged plans
Side
Price · $BBIO · 12Mvia TradingView
Top insiders · 12m
Cook Jennifer E.—3× · $21.9M
Kumar NeilChief Executive Officer2× · $5.6M
Apuli MaricelChief Accounting Officer1× · $160K
Valantine Hannah—1× · $342K
Ellis Andrea—1× · $1.4M
All insider trades
8 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Jul 30, 2026 | Apuli MaricelChief Accounting Officer · O | ▼ Sale | 2,000 | $80.06 | $160K | -1.5% | plan |
| Jul 9, 2026 | Ellis AndreaD | ▼ Sale | 17,167 | $84 | $1.4M | -43.2% | plan |
| Jul 9, 2026 | Cook Jennifer E.D | ▼ Sale | 148,589 | $88.54 | $13.2M | -94.7% | plan · 2 tranches |
| Jun 24, 2026 | Cook Jennifer E.D | ▼ Sale | 39,363 | $69.92 | $2.8M | -82.4% | plan · 2 tranches |
| Jun 23, 2026 | Valantine HannahD | ▼ Sale | 5,004 | $68.25 | $342K | -35.1% | plan · 2 tranches |
| Jun 15, 2026 | Cook Jennifer E.D | ▼ Sale | 90,240 | $66.62 | $6.0M | -93.2% | plan · 2 tranches |
| Jun 5, 2026 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 80,000 | $67.67 | $5.4M | -1.8% | plan · 14 tranches · indirect |
| May 21, 2026 | Kumar NeilChief Executive Officer · O·D | ▼ Sale | 2,256 | $67.57 | $152K | -0.8% | plan |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $BBIO feed.